Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352886 | 0.88 | TSHR (0.68) | TSHRHTTKMT2AMEN1GAA | |
| SCHEMBL1930296 | 0.86 | MEN1 (0.70) | TSHRHTTKMT2AMEN1GAA | |
| SCHEMBL5533585 | 0.84 | L3MBTL1 (0.69) | TSHRHTTKMT2AMEN1GAA | |
| SCHEMBL13501824 | 0.84 | KMT2A (0.69) | TSHRHTTKMT2AMEN1GAA | |
| SCHEMBL316093 | 0.83 | KMT2A (0.76) | TSHRHTTKMT2AMEN1GAA | |
| SCHEMBL27722453 | 0.83 | KMT2A (0.76) | TSHRHTTKMT2AMEN1GAA | |
| SCHEMBL8632489 | 0.82 | GAA (0.65) | TSHRHTTKMT2AMEN1GAA | |
| Hydrochloric Acid SCHEMBL4846563 | 0.82 | KMT2A (0.73) | TSHRHTTKMT2AMEN1GAA | |
| SCHEMBL1574735 | 0.82 | KMT2A (0.73) | TSHRHTTKMT2AMEN1GAA | |
| SCHEMBL12585052 | 0.81 | MAPK1 (0.79) | TSHRHTTKMT2AMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| WO-2013059582-A2 | SMALL MOLECULE INHIBITORS OF HISTONE DEACTEYLASES | NUPOTENTIAL, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| WO-2009055917-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | TSHR 2697/4885HTT 878/4885KMT2A 60/4885 |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | TSHR 2697/4885HTT 878/4885KMT2A 60/4885 |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | HELZ, MMEL1, GAA | TSHR 3494/4885HTT 3076/4885KMT2A 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.